Table 2.

5-year Overall Survival and Disease-Specific Survival by Anatomic and Prognosis Stage of TNBCs included in SEER cohort (N = 31,941)

	Stage	No. at risk	5-year OS (95% CI)	p-value	No. at risk	5-year DSS (95% CI)	p-value
AS	I	12,700	87.2(86.2,88.0)	< 0.001**	12,700	93.5(82.8,94.2)	< 0.001**
	IA	12,293	87.4(86.5,88.3)	0.004*	12,293	93.8(93.1,94.4)	0.001*
	IB	407	80.4(73.9,85.5)		407	86.2(80.6,90.2)
	II	14,292	75.3(74.2,76.4)	< 0.001#	14,292	82.7(81.8,83.7)	< 0.001#
	IIA	9713	78.5(77.2,79.7)		9713	86.0(84.9,87.0)
	IIB	4579	68.3(66.1,70.4)		4579	75.5(73.5,77.4)
	III	4949	46.8(44.8,48.7)	< 0.001△	4949	54.0(52.0,56.0)	< 0.001△
	IIIA	2515	57.1(54.3,59.7)		2515	63.6(60.8,66.2)
	IIIB	1164	38.5(34.5,42.5)		1164	47.0(42.6,51.2)
	IIIC	1270	34.3(30.5,38.2)		1270	41.4(37.3,45.2)
PS	I	12,293	87.4(86.5,88.3)	< 0.001**	12,293	93.8(93.1,94.4)	< 0.001**
	IA	407	89.4(83.6,93.2)	0.212*	407	94.6(89.2,97.3)	0.259*
	IB	11,886	87.4(86.5,88.3)		11,886	93.8(93.1,94.4)
	II	10,726	77.9(76.7,79.1)	< 0.001#	10,726	85.5(84.4,86.5)	< 0.001#
	IIA	10,120	78.6(77.3,79.8)		10,120	86.0(85.0,87.0)
	IIB	606	67.4(61.2,72.9)		606	75.4(69.3,80.4)
	III	8922	56.3(54.8,57.8)	< 0.001△	8922	63.5(62.0,65.0)	< 0.001△
	IIIA	3986	68.7(66.4,70.8)		3986	75.6(73.4,77.6)
	IIIB	365	56.3(47.8,64.0)		365	62.1(53.0,70.0)
	IIIC	4571	45.9(43.9,48.0)		4571	53.3(51.2,55.4)

**Log-rank test comparing proportions among all stage;*Log-rank test comparing proportions among Stage I; ^#Log-rank test comparing proportions among Stage II; ^△Log-rank test comparing proportions among Stage III

TNBC triple negative breast cancer, AS anatomic stage, PS prognosis stage, OS overall survival, DSS disease specific survival, CI confidence interval